Evidence map›Paper›PMID 32774739›Full record

ArticleAmerican journal of translational research2020

Down-regulation of PCK2 inhibits the invasion and metastasis of laryngeal carcinoma cells.

Yun Hu, Kun Deng, Meihong Pan, Shanyan Liu, Wenda Li, Jialu Huang, Jinwei Yao, Jianhong Zuo

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of translational research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Cancer biology & therapy · 2025
    Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Foods (Basel, Switzerland) · 2022
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yun HuHunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, The Laboratory of Translational Medicine, Hunan Provincial Key Laboratory of Tumour Microenvironment Responsive Drug Research, Hengyang Medical School, University of South China Hengyang 421002, Hunan, P. R. China.
Kun DengHunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, The Laboratory of Translational Medicine, Hunan Provincial Key Laboratory of Tumour Microenvironment Responsive Drug Research, Hengyang Medical School, University of South China Hengyang 421002, Hunan, P. R. China.
Meihong PanThe Affiliated Nanhua Hospital of University of South China Hengyang 421002, Hunan, P. R. China.
Shanyan LiuThe Affiliated Nanhua Hospital of University of South China Hengyang 421002, Hunan, P. R. China.
Wenda LiHunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, The Laboratory of Translational Medicine, Hunan Provincial Key Laboratory of Tumour Microenvironment Responsive Drug Research, Hengyang Medical School, University of South China Hengyang 421002, Hunan, P. R. China.
Jialu HuangHunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, The Laboratory of Translational Medicine, Hunan Provincial Key Laboratory of Tumour Microenvironment Responsive Drug Research, Hengyang Medical School, University of South China Hengyang 421002, Hunan, P. R. China.
Jinwei YaoThe Third Affiliated Hospital of University of South China Hengyang 421900, Hunan, P. R. China.
Jianhong ZuoHunan Province Key Laboratory of Tumor Cellular and Molecular Pathology, Cancer Research Institute, The Laboratory of Translational Medicine, Hunan Provincial Key Laboratory of Tumour Microenvironment Responsive Drug Research, Hengyang Medical School, University of South China Hengyang 421002, Hunan, P. R. China.
University of South China · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Laryngeal carcinoma is one of the common malignancies of head and neck. However, the pathogenesis of laryngeal cancer has been not completely clear. To identify the effects of hypoxia on the invasion, metastasis, and metabolism of laryngeal carcinoma, iTRAQ-labeling-with-LC-MS/MS analysis was performed to identify differentially expressed proteins of the SCC10A cells under hypoxia and normoxia, while metabolites were examined by metabolic profiling. 155 proteins and 180 metabolites were identified and the PCK2 protein was selected for validation by Western Blotting. Immunohistochemistry (IHC) was performed to analyze the expression of PCK2 in formalin-fixed paraffin-embedded (FFPE) tissue sections, including laryngeal squamous cell carcinoma tissues from various stages. Collectively, we report that down-regulation of PCK2 inhibits the invasion, migration, and proliferation of laryngeal cancer under hypoxia and down-regulation of PCK2 may be used as a new strategy for laryngeal cancer therapy.

Indexed as

hypoxiainvasionLaryngeal cancermetastasisPCK2

Identifiers

PMID32774739
PMCPMC7407686
OpenAlexW3049236877

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.